The 2021 list of medical technologies approved for innovation funding (NUB) released in Germany

On January 29, 2021, the Institute for the Hospital Remuneration System (InEK) has published the List of the requests for innovation funding (NUB) that were submitted by the hospitals in 2020.

Out of 818 submitted technologies, 213 (26%) received the positive status 1, which means that the suggested procedure or medical device met the NUB criteria, so now the hospitals can negotiate the innovation funding for these technologies with the sickness funds.

Furthermore, 36 (4%) technologies received differentiated status, which means that status 1 can be granted only under certain conditions.

The full list of medical technologies (n=78, excluding pharmaceuticals), which obtained status 1, is provided below. The technologies are listed according to the number of received applications for funding. The technologies with differentiated status were not included in the list.

1. Insertion of coated (covered) stents with a bioactive surface for peripheral vessels
2. Covered endoprosthesis with a bioactive surface for dialysis shunt revision
3. Ascites treatment using a fully implantable pump
4. External stabilization scaffold for anastomosis of an AV shunt as part of shunt surgery
5. Endovascular system of an internal AV shunt using magnetically guided radiofrequency energy
6. Hemodynamically effective implant for the endovascular treatment of intracranial aneurysms and brain-supplying neck vessels
7. Intra-aneurysmal hemodynamically effective implant for endovascular treatment of intracranial aneurysms
8. Flow-reducing wire mesh in the coronary sinus
9. Removable, ultra-soft microcoils for intracranial therapy of vascular malformations and aneurysms
10. The intra-aortic catheter with paracorporeal membrane pump for circulatory support of the left ventricle
11. Gastric pacemaker implantation
12. Extra-corporeal neurostimulation system for the peripheral nervous system
13. Percutaneous transluminal insertion of an atrial septal implant for the treatment of heart failure
14. Transfer of virus-specific donor immune cells after allogeneic stem cell transplantation
15. Therapy of scoliosis using magnetically controlled rods
16. Focal photodynamic therapy with padeliporfin for the treatment of localized prostate cancer
17. Transcatheter implantation of an interatrial shunt device for the treatment of heart failure
18. Endovascular implantation of an extra-corporeal centrifugal pump for circulatory support
19. Mesenchymal stem cells
20. Transapical mitral valve reconstruction by implantation of neochordae (PTFE)
21. Vertebral bodies growth modulation technique
22. Temporomandibular joint endoprosthesis (total replacement)
23. Endovascular mitral valve annuloplasty with an annuloplasty band
24. Administration of CAR-T cells for the treatment of hematological diseases
25. Minimally invasive LV-reconstruction with a myocardial anchoring system
26. Intra-aortal balloon occlusion with extra-corporeal circulation
27. Catheter-based implant for the treatment of left ventricular cardiac motility disorders
28. Insertion of coated (covered) stents with a bioactive surface for peripheral and other vessels
29. Wireless left ventricular cardiac pacing system for cardiac resynchronization therapy
30. Implantation of growing heart valves
31. Therapy of scoliosis using a screw and rod system that grows with the patient
32. Endo-Exo-Prostheses
33. Replacement of the pulmonary trunk or parts of the aorta with an acellular allograft
34. Percutaneous transluminal implantation of an interatrial shunt for the treatment of heart failure with preserved or reduced left ventricular ejection fraction
35. Forming of a sleeve stomach (sleeve resection), endoscopic
36. Endovascular forming of a peripheral AV fistula via direct current
37. Radioligand therapy with Actinium-225-PSMA-ligands
38. Insertion of coated (covered) stents with a bioactive surface for intraabdominal, cranial, or peripheral vessels
39. Implant for direct acoustic stimulation of the cochlea (DACI)
40. Apicoaortal valve-carrying conduit
41. Insertion of coated (covered) stents with a bioactive surface for visceral and supra-aortic vessels
42. Acoustic neurinoma surgery with simultaneous cochlear implantation
43. Endovascular implantation of a stent-graft with valve element for tricuspid valve regurgitation
44. Fetoscopic drainage therapy
45. Radioimmunotherapy with anti-CD19, anti-CD45, and anti-CD66 antibodies
46. Epiretinal retinal prosthesis
47. Endovascular mitral valve annuloplasty with seam anchoring
48. Fetoscopic tracheal balloon occlusion in diaphragmatic hernia and premature bladder rupture
49. Intracavitary radiotherapy with Iodine-125
50. Lutetium-177- or Yttrium-90-pentixafor therapy
51. Pulmonary arterial banding, telemetrically adjustable
52. Closure of umbilical cord and intrafetal vessels by percutaneous ultrasound-controlled radiofrequency ablation or fetoscopic laser ablation
53. Boston keratoprosthesis
54. Fetoscopic opening of narrowed semilunar valves and the foramen ovale
55. Auditory brainstem implant
56. Fetoscopic therapy of fetal supraventricular tachycardia and larynx or trachea occlusion
57. Thyroplasty implant with the possibility of postoperative adjustment of vocal fold position
58. Keratoprosthesis, biologically coated
59. Growth endoprosthesis
60. Continuous amniotic infusion using the subcutaneously implanted port system
61. Radionuclide therapy with lutetium-177-bisphosphonate in bone metastases of prostate cancer
62. Uterine shield closure after fetoscopic interventions
63. Allogenic hepatocytes transplantation
64. Artificial larynx after total laryngectomy
65. Percutaneous-transthoracic tricuspid valve replacement
66. Uterus transplantation
67. Auditory middle brain implant
68. Percutaneous caval valve stent placement
69. Radionuclide therapy with Iodine-131-azetidinylamide in metastatic adrenal carcinoma
70. Subretinal active implant
71. Autologous matrix-induced hepatocytes transplantation
72. Treatment of fatal epidermolysis bullosa junctionalis (M. Herlitz type) by transplantation of haploidentical bone marrow and skin of the same donor
73. Treatment of children with rhabdomyosarcomas of the bladder/prostate/rectum / perineal region with organ-preserving surgery and interstitial HDR brachytherapy
74. Joint transplants with thin-layered, fresh, living, allogeneic cartilage or bone material
75. Gene therapy with autologous CD34+ enriched cells with ARSAGs for the treatment of metachromatic leukodystrophy
76. Combined renal and stem cell transplantation (living donation)
77. Radionuclide therapy with Iodine-131-metomidate
78. Complete face transplantation

Four new technologies (percutaneous transluminal implantation of an interatrial shunt for the treatment of heart failure with preserved or reduced left ventricular ejection fraction, endovascular implantation of a stent-graft with valve element for tricuspid valve regurgitation, thyroplasty implant with the possibility of postoperative adjustment of vocal fold position, gene therapy with autologous CD34+ enriched cells with ARSAGs for the treatment of metachromatic leukodystrophy) received status 1 in comparison with the 2020 list.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.